A treatment strategy for KRAS-driven tumors

Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: The effect of SHP2 on the RTK–KRAS–MAPK signaling pathway.


  1. 1.

    Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Cancer Cell 25, 272–281 (2014).

  2. 2.

    Mainardi, S. et al. Nat. Med. (2018).

  3. 3.

    Ruess, D. A. et al. Nat. Med. (2018).

  4. 4.

    Wong, G. S. et al. Nat. Med. (2018).

  5. 5.

    Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).

  6. 6.

    Patricelli, M. P. et al. Cancer Discov. 6, 316–329 (2016).

  7. 7.

    Lito, P. et al. Cancer Cell 25, 697–710 (2014).

  8. 8.

    Ran, H., Tsutsumi, R., Araki, T. & Neel, B. G. Cancer Cell 30, 194–196 (2016).

  9. 9.

    Chen, Y. N. et al. Nature 535, 148–152 (2016).

  10. 10.

    Dardaei, L. et al. Nat. Med. 24, 512–517 (2018).

  11. 11.

    Drosten, M. et al. EMBO J. 29, 1091–1104 (2010).

  12. 12.

    Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).

Download references


P.L. is supported by the National Institutes of Health (K08 CA191082-01A1), the Damon Runyon Cancer Research Foundation (Clinical Investigator Award), the LUNGevity Foundation (Career Development Award) and the V Foundation (Translational Grant).

Author information

Correspondence to Piro Lito.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mai, T.T., Lito, P. A treatment strategy for KRAS-driven tumors. Nat Med 24, 902–904 (2018).

Download citation

Further reading